Kovack Advisors’s bluebird bio BLUE Stock Holding History

Kovack Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-102	Closed	-$208K	–	483
2019 Q1	$208K	Buy	+102	New	+$180K	0.05%	370

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kovack Advisors's BLUE Position: Q2 2019 in Review

Kovack Advisors sold out of bluebird bio (BLUE) in Q2 2019, closing a stake of 102 shares — an estimated $208K sold.

Kovack Advisors first reported a position in BLUE in Q1 2019 and held it in 1 quarter. The position peaked at $208K in Q1 2019. 273 funds tracked by Wall St. Rank hold BLUE as of Q2 2019.

Kovack Advisors reported no remaining bluebird bio position as of Q2 2019 after selling out during the quarter.
Kovack Advisors sold 102 bluebird bio shares in Q2 2019, an estimated $208K.
Kovack Advisors first reported a position in bluebird bio in Q1 2019 and held it in 1 quarter.
Kovack Advisors's bluebird bio position peaked at $208K in Q1 2019.
273 funds tracked by Wall St. Rank held bluebird bio as of Q2 2019.

Based on Kovack Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.